Citigroup’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.2M | Buy |
442,000
+120,000
| +37% | +$5.69M | 0.01% | 1188 |
|
|
2025
Q4 | $16.4M | Sell |
322,000
-52,000
| -14% | -$2.66M | 0.01% | 1216 |
|
|
2025
Q3 | $20.8M | Buy |
374,000
+194,000
| +108% | +$11.4M | 0.01% | 1040 |
|
|
2025
Q2 | $12.4M | Sell |
180,000
-115,000
| -39% | -$7.82M | 0.01% | 1245 |
|
|
2025
Q1 | $20.5M | Buy |
295,000
+22,400
| +8% | +$1.85M | 0.01% | 960 |
|
|
2024
Q4 | $23.4M | Buy |
272,600
+174,600
| +178% | +$18.9M | 0.01% | 861 |
|
|
2024
Q3 | $11.7M | Buy |
+98,000
| New | +$13.1M | 0.01% | 1247 |
|
|
2024
Q2 | – | Sell |
-21,600
| Closed | -$2.77M | – | 5719 |
|
|
2024
Q1 | $2.77M | Buy |
21,600
+14,100
| +188% | +$1.68M | ﹤0.01% | 2160 |
|
|
2023
Q4 | $776K | Sell |
7,500
-33,600
| -82% | -$3.32M | ﹤0.01% | 3052 |
|
|
2023
Q3 | $3.74M | Buy |
+41,100
| New | +$3.62M | ﹤0.01% | 1585 |
|
|
2022
Q3 | – | Sell |
-103,400
| Closed | -$5.76M | – | 6182 |
|
|
2022
Q2 | $5.76M | Buy |
+103,400
| New | +$5.74M | ﹤0.01% | 1457 |
|
|
2021
Q1 | – | Sell |
-176,800
| Closed | -$6.17M | – | 7042 |
|
|
2020
Q4 | $6.17M | Buy |
176,800
+131,000
| +286% | +$4.53M | ﹤0.01% | 1922 |
|
|
2020
Q3 | $1.59M | Sell |
45,800
-57,800
| -56% | -$1.93M | ﹤0.01% | 2868 |
|
|
2020
Q2 | $3.39M | Sell |
103,600
-97,200
| -48% | -$3.1M | ﹤0.01% | 2231 |
|
|
2020
Q1 | $6.04M | Buy |
200,800
+61,600
| +44% | +$1.83M | 0.01% | 1516 |
|
|
2019
Q4 | $4.03M | Buy |
139,200
+27,600
| +25% | +$764K | ﹤0.01% | 2225 |
|
|
2019
Q3 | $2.88M | Sell |
111,600
-8,000
| -7% | -$202K | ﹤0.01% | 2470 |
|
|
2019
Q2 | $3.05M | Sell |
119,600
-16,200
| -12% | -$400K | ﹤0.01% | 2384 |
|
|
2019
Q1 | $3.55M | Sell |
135,800
-227,000
| -63% | -$5.58M | ﹤0.01% | 2087 |
|
|
2018
Q4 | $8.36M | Buy |
362,800
+263,400
| +265% | +$5.85M | 0.01% | 1393 |
|
|
2018
Q3 | $2.34M | Sell |
99,400
-63,800
| -39% | -$1.56M | ﹤0.01% | 2592 |
|
|
2018
Q2 | $3.76M | Buy |
163,200
+68,200
| +72% | +$1.62M | ﹤0.01% | 2106 |
|
|
2018
Q1 | $2.33M | Sell |
95,000
-127,600
| -57% | -$3.35M | ﹤0.01% | 2467 |
|
|
2017
Q4 | $5.97M | Buy |
222,600
+94,800
| +74% | +$2.41M | ﹤0.01% | 1664 |
|
|
2017
Q3 | $3.08M | Buy |
127,800
+29,400
| +30% | +$664K | ﹤0.01% | 2209 |
|
|
2017
Q2 | $2.11M | Buy |
98,400
+13,600
| +16% | +$274K | ﹤0.01% | 2532 |
|
|
2017
Q1 | $1.45M | Buy |
84,800
+16,000
| +23% | +$279K | ﹤0.01% | 2807 |
|
|
2016
Q4 | $1.23M | Buy |
68,800
+13,400
| +24% | +$243K | ﹤0.01% | 3470 |
|
|
2016
Q3 | $1.15M | Sell |
55,400
-32,600
| -37% | -$808K | ﹤0.01% | 3071 |
|
|
2016
Q2 | $2.37M | Buy |
88,000
+15,400
| +21% | +$422K | ﹤0.01% | 2216 |
|
|
2016
Q1 | $1.97M | Buy |
72,600
+35,800
| +97% | +$959K | ﹤0.01% | 2510 |
|
|
2015
Q4 | $1.07M | Buy |
36,800
+34,000
| +1,214% | +$941K | ﹤0.01% | 3059 |
|
|
2015
Q3 | $76K | Buy |
2,800
+2,000
| +250% | +$56.6K | ﹤0.01% | 5156 |
|
|
2015
Q2 | $22K | Buy |
+800
| New | +$22.5K | ﹤0.01% | 6047 |
|
Other funds holding NVO
DAM
F
Citigroup's NVO Position: Q1 2026 in Review
Citigroup increased its Novo Nordisk (NVO) stake by 10% in Q1 2026, buying an estimated $6.72M and bringing the position to 1,547,655 shares worth $56.9M. The position accounts for 0.02% of the portfolio, ranked #592.
Citigroup first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $190M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Citigroup held 1,547,655 shares of Novo Nordisk worth $56.9M as of Q1 2026.
- Citigroup bought 141,931 Novo Nordisk shares in Q1 2026, an estimated $6.72M.
- Novo Nordisk made up 0.02% of Citigroup's portfolio in Q1 2026, its #592 holding.
- Citigroup first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Novo Nordisk position peaked at $190M in Q2 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.